Comparative Analysis Of Postoperative Vault In Staar Icl And Biotech Icl: Long-Term Outcomes At 1, 2, And 3 Years In 50 Patients

The purpose of this study is to compare post operative vault between the Staar ICL and Biotech ICL implants
over a period of 3 years.

We aim to evaluate the impact of different ICL designs on vault stability and long-term visual and anatomical outcomes.
Specifically, this research will assess the vault size's influence on refractive outcomes, complications, and patient
satisfaction, providing clinicians with a clearer understanding of the advantages and potential risks associated with each
ICL type.

Study Type: Prospective, non-randomized, comparative longitudinal study.

Location: single surgeon private practice setup

Participants: 50 patients, with 40 Staar ICL and 10 Biotech ICL

Inclusion Criteria: Patients aged 18-36 with stable refractive errors (myopia, hyperopia, or astigmatism), and suitable for
ICL implantation.

Exclusion Criteria: Patients with corneal pathology, prior eye surgery, or uncontrolled systemic diseases.

Comprehensive eye examination including manifest refraction, visual acuity, slit-lamp biomicroscopy, IOP
measurement, digital WTW measurement and fundus examination, Optical
UCVA, BCVA, refractive error (spherical equivalent), and vault measurement using Anterior Segment OCT will be
assessed at each follow-up.

Vault Comparison:
both designs maintained an ideal vault range in the majority of patients ,Staar ICL showed a slightly higher postoperative
vault (around 417 µm after 3 years) compared to biotech ICL  (390 µm at 3 years).

Conclusions: In this , both Staar ICL and Biotech ICL were successful in providing stable refractive outcomes with
minimal complications over a 3-year period. Staar ICL had a slightly more stable vault, lower complication rates, and
higher patient satisfaction scores. However, both designs were effective in treating high refractive errors with acceptable
safety profiles, making both options viable for clinical practice.